TOXICITY AND HAZARD OF ZOLMITRIPTAN (EXPERIMENTAL STUDY)

Capa

Citar

Texto integral

Resumo

Zolmitriptan is a widely used antimigraine drug, belongs to the group of second-generation tryptans, has a pronounced central mechanism of action and high selectivity to serotonin receptors of 5HT1D- and 5HT1B-types. Zolmitriptan belongs to hazard class 3 according to GOST 12.1.007-76: DL50 are 660 (495 - 881) mg/kg for male mice and 1045 (749 - 1292) mg/kg for female mice when administered into the stomach. When injected into the abdominal cavity, DL50 is 172 (131 - 225) mg/kg for male mice. The drug has a weak irritating effect on the mucous membranes of the eyes, does not irritate the skin, there are no signs of skin-resorptive action, and has a low ability to accumulate. The threshold of acute inhalation action is set at 0,9 mg/m3 for the effect on the functional state of the nervous system and liver. For the zolmitriptan aerosol, it is recommended to approve the tentative safe exposure level in the air of the working area at 0,01 mg/m3 and the tentative safe exposure level in the atmospheric air of urban and rural settlements at 0,0001 mg/m3.

Sobre autores

M. Bidevkina

Scientific Research Disinfectology Institute of Rospotrebnadzor

Autor responsável pela correspondência
Email: bidevkinamv@niid.ru

Bidevkina Marina Vasil’evna

117246, Moscow

Rússia

M. Golubeva

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: golubevamargo@mail.ru

Golubeva Margarita Ivanovna

142450, Staraya Kupavna, Moscow region

Rússia

I. Bobrineva

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: ural955@mail.ru

Bobrineva Irina Alekseevna

142450, Staraya Kupavna, Moscow region

Rússia

A. Limantsev

Scientific Research Disinfectology Institute of Rospotrebnadzor

Email: av.lim@yandex.ru

Limantsev Anatoliy Vladimirovich

117246, Moscow

Rússia

T. Potapova

Scientific Research Disinfectology Institute of Rospotrebnadzor

Email: potapovatn@niid.ru

Potapova Tat›yana Nikolaevna

117246, Moscow

Rússia

I. Razumnaya

Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»

Email: irina.r.3@mail.ru

Razumnaya Irina Nikolaevna

142450, Staraya Kupavna, Moscow region

Rússia

A. Savchenko

Scientific Center for Biomedical Technology of the Federal Medical Biological Agency of the Russian Federation

Email: alursav@mail.ru

Savchenko Аlla Yur’evna

143442, Svetlye Gory Village, Krasnogorsk District, Moscow region

Rússia

G. Ramenskaya

I.M. Sechenov First Moscow State Medical University

Email: ramenskaia@mail.ru

Ramenskaya Galina Vladislavovna

119991, Moscow

Rússia

Bibliografia

  1. Kalashnikova L.A. Zomig – a new selective serotonin receptor agonist in the treatment of migraine attacks. Neurological journal; 1999; 4 (4): 37-40 (in Russian).
  2. Evolution of views on the causes of migraines. International neurological journal; 2009; 5(27). Available at: http://www.mif-ua.com/archive/article_print/11306 (accessed 02 August, 2019) (in Russian).

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bidevkina M.V., Golubeva M.I., Bobrineva I.A., Limantsev A.V., Potapova T.N., Razumnaya I.N., Savchenko A.Y., Ramenskaya G.V., 2020


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.